Home/Protocols/Semaglutide
Protocol Reference
Human trial data

Semaglutide protocol

Semaglutide (GLP-1 receptor agonist). Dosing on this page comes from a published human trial or an approved product label, cited below.

Category
GLP-1 & Metabolic
Common vials
10, 15, 20, 30, 50 mg
Half-life
~7 days
Route in the literature
Subcutaneous, once weekly
Evidence level
Human trial data

How Semaglutide works

A GLP-1 receptor agonist carrying a fatty-acid chain that binds albumin and stretches its half-life to about a week. It slows gastric emptying, increases glucose-dependent insulin secretion, and acts on hypothalamic appetite centres.

Semaglutide dosing schedule

The escalation below is the one used in the STEP phase 3 obesity programme and carried onto the approved weight-management label. It exists to limit gastrointestinal effects — the trials escalated slowly for tolerability, not because the lower steps do more.

PhaseAmountFrequencyNotes
Weeks 1–40.25 mgOnce weeklyTolerability lead-in, not an intended effective amount.
Weeks 5–80.5 mgOnce weeklyFirst escalation.
Weeks 9–121.0 mgOnce weekly
Weeks 13–161.7 mgOnce weekly
Week 17 onward2.4 mgOnce weeklyMaintenance amount for the remainder of the trial.

Study length: 68 weeks in STEP 1, with the maintenance amount reached at week 17.

Source for this schedule: Wilding JPH et al., "Once-Weekly Semaglutide in Adults with Overweight or Obesity", NEJM 2021 (STEP 1). This reproduces what was administered in that work. It is reference information about a study, not a recommendation, and the trial population, monitoring and endpoints are part of what made it a protocol.

Reconstitution and measurement

This part is arithmetic and does not depend on the evidence level. Concentration is vial size divided by the bacteriostatic water you add. Draw volume is your target amount divided by that concentration. Units are draw volume times 100, because a U-100 syringe reads 100 units per millilitre. Common vials for Semaglutide: 10, 15, 20, 30, 50 mg.

Open the Semaglutide calculator → Unit converter

Storage and stability

Dry powder
Cold, dark and dry. Lyophilized peptide is the stable form — keep it that way until you intend to use it.
After reconstitution
Refrigerate at 2–8 °C, protect from light, and plan around a limited window. Do not freeze a reconstituted vial — freeze-thaw damages peptides.
Mixing
Run bacteriostatic water down the inside wall of the vial rather than onto the powder, then swirl. Never shake.
Inspect before use
A clear solution is expected. Cloudiness or particles mean discard, not use.

Full storage guide → · Cloudy solution?

Reported effects

  • Gastrointestinal effects — nausea, vomiting, diarrhoea, constipation — were the most frequently reported events in STEP 1 and are the reason for the slow escalation.
  • Trial reporting notes gallbladder-related events more often than placebo.
  • Labels in this drug class carry a boxed warning about thyroid C-cell tumours seen in rodents; human relevance is not established.

Sourcing Semaglutide

Whatever you are working with, the documentation matters more than the price. Ask for a batch certificate of analysis whose lot number matches the vial you actually receive — a COA for a different batch tells you nothing about yours.

Semaglutide at Summit Research Supply → Grade a COA first

Summit is the supplier we feature and an affiliate link. Our COA checklist applies the same way to any vendor.

For laboratory research use only. This page documents what the published literature reports about Semaglutide. It is not a recommendation, not a treatment plan, and not medical advice. Compounds referenced are sold strictly as research chemicals and are not for human or veterinary use. Some supplier links are affiliate links and may earn us a commission. This never affects tier placement or review conclusions.
Summit Research Supply
Summit Research Supply — COA-verified research peptidesThird-party tested · U.S. fulfillment · new researchers save 10%
Shop →